<p>Conjugate inhibits both androgen receptor and ERK signalling and finally contributing to its downstream effects of decreased cell viability and increased apoptosis in androgen receptor positive LNCaP cells. In case of androgen receptor negative PC-3 cells, inhibition of Akt and its downstream targets contributes to conjugate mediated decrease in cell viability and increased apoptosis.</p
<p>Cell cycle distribution of (A) PC-3 and (B) LNCaP cells upon treatment with varying doses of conj...
Prostate cancer (PC) represents the most common type of cancer among males and is the second leading...
Androgen receptor (AR) is a major drug target in prostate cancer (PCa) therapy. Both supraphysiologi...
<p>Effects of siRNA mediated silencing of Akt and ERK on conjugate-induced apoptosis of (A) PC-3 and...
<p>Effect of conjugate on the transactivation of androgen receptor in presence/absence of 10 nM DHT ...
Chemotherapy and anti-hormonal therapies are the most common treatments for non-organ-confined prost...
The progression to castration-resistant prostate cancer (CRPC) correlates with gain-of-function of t...
<div><p>Chemotherapy and anti-hormonal therapies are the most common treatments for non-organ-confin...
We introduce a family of multivalent peptidomimetic conjugates that modulate the activity of the and...
Prostate cancer is the second most leading cause of cancer-related death among American men. The exp...
Androgen ablation is the standard treatment for advanced disease. Despite initial success, approxima...
Androgen deprivation therapy (ADT) is the first-line treatment to metastatic prostate cancer (PCa). ...
Background: Androgen deprivation therapy (ADT) is the first-line treatment to metastatic prostate ca...
<p>(A) Immunoblot analysis for the expression of androgen receptor co-regulators in response to conj...
In order to generate genomic signals, the androgen receptor (AR) has to be transported into the nucl...
<p>Cell cycle distribution of (A) PC-3 and (B) LNCaP cells upon treatment with varying doses of conj...
Prostate cancer (PC) represents the most common type of cancer among males and is the second leading...
Androgen receptor (AR) is a major drug target in prostate cancer (PCa) therapy. Both supraphysiologi...
<p>Effects of siRNA mediated silencing of Akt and ERK on conjugate-induced apoptosis of (A) PC-3 and...
<p>Effect of conjugate on the transactivation of androgen receptor in presence/absence of 10 nM DHT ...
Chemotherapy and anti-hormonal therapies are the most common treatments for non-organ-confined prost...
The progression to castration-resistant prostate cancer (CRPC) correlates with gain-of-function of t...
<div><p>Chemotherapy and anti-hormonal therapies are the most common treatments for non-organ-confin...
We introduce a family of multivalent peptidomimetic conjugates that modulate the activity of the and...
Prostate cancer is the second most leading cause of cancer-related death among American men. The exp...
Androgen ablation is the standard treatment for advanced disease. Despite initial success, approxima...
Androgen deprivation therapy (ADT) is the first-line treatment to metastatic prostate cancer (PCa). ...
Background: Androgen deprivation therapy (ADT) is the first-line treatment to metastatic prostate ca...
<p>(A) Immunoblot analysis for the expression of androgen receptor co-regulators in response to conj...
In order to generate genomic signals, the androgen receptor (AR) has to be transported into the nucl...
<p>Cell cycle distribution of (A) PC-3 and (B) LNCaP cells upon treatment with varying doses of conj...
Prostate cancer (PC) represents the most common type of cancer among males and is the second leading...
Androgen receptor (AR) is a major drug target in prostate cancer (PCa) therapy. Both supraphysiologi...